Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pranith Perera

Gastroenterology Ann Arbor, MI Medical Doctor

NPI 1831361591 CMS profile 264517

1500 E Medical Center Drive, 2Nd Floor University Hospital Recp 2B355, Ann Arbor, MI 48109

Open in the dashboard

General payments

$14,450

238 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pranith Perera of Ann Arbor, MI is reported in the CMS Open Payments database as having received $14,450 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,291 60
2024 General $925 39
2023 General $4,328 51
2022 General $368 24
2021 General $614 27
2020 General $1,146 6
2019 General $5,778 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pranith Perera
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Pranith Perera were reported at $1,291. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Pranith Perera Gastroenterology median Middle half National median
2019 $5,778 $417 $126–$1,100 $163
2020 $1,146 $224 $74–$624 $114
2021 $614 $352 $106–$1,054 $132
2022 $368 $448 $129–$1,270 $149
2023 $4,328 $533 $150–$1,390 $160
2024 $925 $605 $160–$1,606 $164
2025 $1,291 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $9,369 22 payments
  2. AbbVie, Inc. $1,803 132 payments
  3. GI Supply, Inc. $1,162 2 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $432 18 payments
  5. Janssen Biotech, Inc. $354 16 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $226 10 payments
  7. Braintree Laboratories, Inc. $189 3 payments
  8. Pfizer Inc. $164 8 payments
  9. Phathom Pharmaceuticals, Inc. $125 1 payment
  10. Celgene Corporation $113 5 payments
  11. Other $512 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,700 5 payments
  2. Food and Beverage $4,875 226 payments
  3. Honoraria $1,050 1 payment
  4. Travel and Lodging $823 5 payments
  5. Education $2 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL BILIARY DEVICES $4,593 5 payments
  2. RINVOQ $787 55 payments
  3. ACQUIRE $466 2 payments
  4. SKYRIZI Immunology $403 26 payments
  5. LINZESS $385 38 payments
  6. HUMIRA $332 19 payments
  7. CREON $319 36 payments
  8. SKYRIZI Immunology $317 20 payments
  9. STELARA $262 13 payments
  10. ENTYVIO $246 10 payments
  11. Other $2,840 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

299

Median for Gastroenterology: 569

Drug cost

$39,329

Median for Gastroenterology: $104,976

Branded share of claims

16.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 25 $24,214
Motegrity Prucalopride Succinate Brand 12 $7,632
Dexlansoprazole Dr Dexlansoprazole Brand 13 $3,653
Omeprazole Generic 130 $2,305
Esomeprazole Magnesium Generic 15 $827
Pantoprazole Sodium Generic 35 $358
Famotidine Generic 36 $258
Ciprofloxacin Hcl Generic 33 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$55,713

Medicare's payments for the services billed

Medicare patients

240

Average age 73

Services billed

528

136 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 33%
Depression 30%
Ischemic heart disease 28%
Chronic kidney disease 28%
Atrial fibrillation 22%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $125
$125 — —
SKYRIZI
  • AbbVie, Inc. $109
$109 — —
RINVOQ
  • AbbVie, Inc. $100
$100 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $80
$80 — —
ZEPOSIA
  • Celgene Corporation $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record